Clinical CHD Therapy - Early Clinical Trial Unit
- Deutsches Herzzentrum München
- Adnan Kastrati
The objective is 2 fold: evaluation of new therapeutic concepts for the prevention of stent thrombosis and restenosis. A new substance, a glycoproten VI inhibitor, Revacept, which prevents the adhesion of platelets to the vessel wall injury site, is expected to protect against thrombosis without impacting significantly on bleeding. Preclinical and phase I studies have shown promise that Revacept might be an effective and safe drug for prevention of thrombotic events after percutaneous coronary intervention. This substance will be assessed in a phase II clinical trial. The second objective is the development of safer and effective drug-eluting stents. RGD peptide and novel fully resorbable polymers will be subject of pre-clinical and first-in-man studies. We are establishing an early clinical trial unit for the conductance of these studies.
- Coronary artery disease, thrombosis, restenosis, platelet, aggregation, stent, women,antiproliferative drug, antiplatelet drug, clinical trial, phase II
- € 1.308.270,36